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Understanding how comorbidities contribute to death in cancer patients is becoming an important 
topic. the present study assessed the role of comorbidities in overall mortality and causes of death 
in patients with differentiated thyroid carcinoma (DTC). This retrospective cohort study included 
2070 patients who underwent thyroidectomy for DTC at a single institution between 2002 and 2005. 
Probabilities of overall, DTC-specific and other-cause death were examined according to the number of 
comorbidities, with consideration for competing events. The estimated 15-year cumulative incidences 
of overall, DTC-specific, and other-cause death were 7.3%, 1.6%, and 5.7%, respectively. Taking the 
group without comorbidities as a reference, we found that the group with 1–2 comorbidities and the 
group with ≥3 comorbidities had higher probabilities of other-cause death (subhazard ratios = 2.48 
and 9.41, respectively; p < 0.01) and consequently shorter overall survival (hazard ratio = 1.95 and 
5.33, respectively; p < 0.01), with adjustment for age, sex, and tumor-node-metastasis classification. 
In contrast, the probability of DTC-specific death was reduced in patients with ≥3 comorbidities 
(subhazard ratio = 6.81e-10, p < 0.01). For overall death, the relative proportion of death from DTC 
reduced when the number of comorbidities increased, and DTC-specific death was not observed 
in patients with ≥3 comorbidities. Our results show that death from DTC itself accounted for only 
a fraction of the overall deaths among patients who underwent surgery for DTC. Comorbidities 
increased overall mortality by increasing the probability of other-cause death. Patients with multiple 
comorbidities had a low probability of dying from DTC because they died earlier from comorbidities.
Comorbidities are coexisting medical conditions in a patient who has an index disease of interest1. Patients with 
cancer are often diagnosed with comorbidities that can reduce their overall survival2,3. Comorbidities are known 
to increase the rates of non-cancer deaths (death from non-cancer causes in patients with cancer) and have a 
greater impact on the survival of patients with less severe cancers2.
Differentiated thyroid carcinoma (DTC) is understood to be relatively indolent. The majority of patients with 
DTC are in stage I or II according to the American Joint Committee on Cancer/Union for International Cancer 
Control (AJCC/UICC) staging system, with a 10-year disease-specific survival of more than 90%4–7. However, the 
overall survival of patients with DTC is significantly lower than disease-specific survival, and the 10-year overall 
survival of patients in AJCC/UICC stage II was reported to be only 71%5. This observation suggests that there 
may be a large contribution of comorbidities toward the death of patients with DTC. Nevertheless, little is known 
about the role of comorbidities in leading to death in patients with DTC. The aim of this study is to evaluate the 
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predictive ability of comorbidities at the time of surgery for the overall mortality and the cause of death in patients 
with DTC.
Materials and Methods
patients. We performed a single-center, retrospective cohort study that included patients who underwent 
thyroidectomy (total thyroidectomy or hemi-thyroidectomy) for DTC between 2002 and 2005 at Severance 
Hospital in Seoul, Republic of Korea. Only patients with pathologically proven papillary thyroid carcinoma, fol-
licular thyroid carcinoma, and Hurthle cell thyroid carcinoma were included in this study; patients with other 
types of thyroid cancer were excluded. In addition, patients with noninvasive follicular thyroid neoplasm with 
papillary-like nuclear features (NIFTP) or those with papillary thyroid microcarcinoma (size < 1 cm) without 
lymph node metastases or distant metastases were excluded to minimize the influence of data from patients with 
tumors carrying minimal expected disease-specific mortality.
Classifications for thyroid cancer, comorbidities, and outcomes. The medical records of all patients 
were manually reviewed. Patients were retrospectively reclassified according to the eighth edition of AJCC/UICC 
tumor-node-metastasis (TNM) classification system8. For all patients, history taking and routine workup (e.g., 
electrocardiogram, chest radiograph, serum glucose, creatinine, aspartate transaminase, alanine transaminase, 
and total bilirubin) were thoroughly performed before surgery to assess operability. Patients with a history of 
comorbidities or suspected comorbidities found during the routine workup were referred to relevant specialists; 
additional examinations (e.g., echocardiography, coronary angiography, pulmonary function test) and treatments 
were conducted as needed before surgery.
Diseases mentioned in the patient’s past history or diagnosed during preoperative workup were considered to 
be baseline comorbidities. We identified baseline comorbidities as follows: malignancies other than DTC, hyper-
tension (HTN), acute coronary syndrome (myocardial infarction and unstable angina), coronary artery occlusive 
disease (coronary artery disease proven through coronary angiography, as well as acute coronary syndrome), con-
gestive heart failure, peripheral vascular disease, cerebrovascular accident, valvular heart disease (grade III and 
IV), aortic dissection, atrial fibrillation, diabetes mellitus (DM), chronic viral hepatitis, liver cirrhosis, asthma, 
chronic obstructive lung disease, end-stage renal disease, connective tissue disease, dementia, plegia (hemiplegia, 
paraplegia, and quadriplegia), peptic ulcer disease, and acquired immunodeficiency syndrome (AIDS). Most of 
these baseline comorbidities were comorbid conditions described by Charlson et al.9.
Survival status during the follow-up period through March 5, 2018 was assessed. To determine survival status 
and cause of death, we additionally reviewed the in-hospital survival-database, which has been built for appro-
priate medical care and follow-up. The in-hospital survival-database included records of telephonic interviews 
with patients or family members of patients, patients’ qualification for the National Health Insurance (NHI) of 
the Republic of Korea, as well as the date and cause of death of patients according to the Korean Central Cancer 
Registry (KCCR) database. The NHI system of the Republic of Korea is a mandatory universal health insurance 
system that covers the entire Korean population. On death, patients automatically lose qualification for the NHI. 
The KCCR was started by the Ministry of Health and Welfare in the Republic of Korea in 1980 and then expanded 
nationwide; it covers more than 95% of cancer patients in the Republic of Korea10. Patients with valid qualification 
for the NHI were classified as alive. If a patient was not qualified for the NHI but their death was not proven by 
any of the medical records, records of telephonic interviews, or the KCCR database, the patient’s data were con-
sidered to be censored at the time of the last follow-up; this situation could occur if the patient was a foreigner, 
was of lost Korean nationality, had immigrated, or if a record of the patient’s death was simply missing from the 
database. Deaths were classified as death from DTC or death from other causes. Death from DTC was defined 
as a case where DTC was the primary cause of death or a complication from DTC was direct cause of death in 
the presence of DTC progression (e.g., death from pneumonia associated with the progression of lung metastasis 
from DTC). Death from other causes was defined as a case in which the primary cause of death was something 
other than DTC or in which no evidence of residual thyroid cancer was observed at the time of death.
Survival analyses for overall mortality. The Kaplan-Meier method was used to generate survival curves 
according to the number of comorbidities for each patient (0, 1–2, and ≥3), while the log-rank test was per-
formed to evaluate differences in overall survival. The combined effects of the T, N, and M classifications of DTC 
and number of comorbidities on overall survival were evaluated using a multivariable Cox proportional hazard 
model with adjustment for age (<55, 55–65, and ≥65 years), sex, and histological type. The validity of the pro-
portional hazards assumption in the Cox model was confirmed using Schoenfeld residuals and parallel curves of 
the log-minus-log plots. The hazard ratios (HR) for overall survival are presented with 95% confidence intervals 
(CIs).
Survival analyses with consideration for competing events. Cumulative incidence plots were gen-
erated for death from DTC and death from other causes with the competing-risks method11,12. The multivariable 
Fine and Gray’s regression model was used to assess the effect of T, N, and M classifications of DTC and the 
number of comorbidities on death from DTC and death from other causes in the presence of competing risks13. 
The subhazard ratios (SHR) for death from DTC and death from other causes are presented with 95% CIs. SHR 
estimates were adjusted for variables that were statistically significant in the preceding multivariable Cox pro-
portional hazard model for overall survival. For generalization, we also performed multivariable Fine and Gray’s 
regression analysis using the Charlson comorbidity index (age and thyroid cancer were not included in the calcu-
lation of the index), instead of the number of comorbidities9. Additionally, stratified cumulative incidence plots 
for death from DTC and death from other causes were generated according to AJCC/UICC TNM stages and the 
number of comorbidities.
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Statistical analyses. Descriptive statistics were presented as means ± standard deviations, medians (inter-
quartile range), and numbers (%) depending on the type of variables.
All tests were two-sided. A P value of <0.05 was considered to be statistically significant. All statistical analy-
ses were performed using SPSS version 23.0 for Windows (IBM Corporation, Armonk, NY, USA) or STATA 14.0 
(Stata Corporation, College Station, TX, USA).
ethics statement. This study was approved by the institutional review board of Severance Hospital, Yonsei 
University College of Medicine in Seoul, Republic of Korea (IRB number: 4-2017-1093). The requirement for 
informed consent was waived for this study.
Results
Baseline characteristics. A total of 2070 patients were enrolled in this study. Table 1 shows the clinico-
pathologic characteristics of patients. Mean age at thyroidectomy was 45.6 ± 13.1 years old, and a female pre-
dominance was observed (84.6%). The median follow-up duration after surgery was 12.8 years (interquartile 
range: 11.7–14.1). A complete follow-up of survival status during the study period was available in 2006 (96.9%) 
patients; in the cohort, the loss to follow-up occurred for the first time 57 months after surgery. T1, T2, T3, and T4 
classifications were noted in 69.4%, 13.4%, 11.3%, and 5.9% of patients, respectively. Also, regarding N classifica-
tion, the frequency was 35.8% for N0, 42.7% for N1a, and 21.4% for N1b. Distant metastasis (M1 classification) 
was observed in 1.0% of patients. The frequency of each TNM stage was 83.8% for stage I, 13.2% for stage II, 
2.6% for stage III, and 0.4% for stage IV. The main histologic type was papillary thyroid carcinoma (98.6%). The 
frequency of each comorbidity was as follows: 87 (4.2%) patients with malignancies other than DTC, 417 (20.1%) 
patients with HTN, 108 (5.2%) patients with DM, and 81 (3.9%) patients with chronic viral hepatitis. Coronary 
artery occlusive disease (including acute coronary syndrome), cerebrovascular accident, congestive heart failure, 
valvular heart disease, aortic dissection, atrial fibrillation, liver cirrhosis (all cases were associated with chronic 
viral hepatitis), asthma, chronic obstructive pulmonary disease, end-stage renal disease, connective tissue disease, 
dementia, and plegia had frequencies between 0.1% and 1.1%, respectively. Peripheral vascular disease, peptic 
ulcer disease, and AIDS were not observed as baseline comorbidities in this study cohort. A total of 607 patients 
(29.3%) had at least one comorbidity.
Death from DTC, death from other causes, and survival. During the follow-up period, 28 cases of 
death from DTC and 95 cases of death from other causes were recorded. Non-thyroid malignancy (n = 37) and 
cardiovascular disease (n = 12) were the first and second most common causes of death other than DTC, respec-
tively (Supplementary Table 1). The 15-year cumulative incidences of death from DTC, death from other causes, 
and overall death were 1.6%, 5.7%, and 7.3%, respectively (Fig. 1). Over the entire observation period, the cumu-
lative incidence of death from other causes was higher than the cumulative incidence of death from DTC.
Role of comorbidities in overall survival. The Kaplan-Meier survival curves revealed differences in over-
all survival rates according to the number of comorbidities for each patient (log-rank, p < 0.01) (Fig. 2). The 
associations between T, N, and M classifications of DTC, the number of comorbidities, and overall survival were 
evaluated using a multivariable Cox regression model (Table 2). Higher T, N, and M classifications were asso-
ciated with a shorter overall survival, as expected (T4 classification, HR = 3.50 [2.19–5.60]; N1b classification, 
HR = 1.69 [1.09–2.60]; and M1 classification, HR = 3.35 [1.49–7.52], with reference to T1, N0, and M0 classi-
fications, respectively; all p < 0.05). However, the number of comorbidities was also independently associated 
with shorter overall survival after adjustment for age (<55, 55–65, and ≥65 years), sex, TNM classifications, and 
histologic types (number of comorbidities 1–2, HR = 1.95 [1.27–2.99]; number of comorbidities ≥3, HR = 5.33 
[2.71–10.46]; both p < 0.01).
Role of T, N, and M classifications of DTC and the number of comorbidities in death from DTC 
and death from other causes. The associations between T, N, and M classifications of DTC, the number 
of comorbidities, and the two types of death (death from DTC and death from other causes) were evaluated using 
Fine and Gray’s regression analyses (Table 3). Older age was associated with a high probability of both death from 
DTC and death from other causes (Age 55–65 years, SHR for death from DTC and death from other causes = 4.83 
[1.40–16.61] and 2.69 [1.51–4.81], respectively; age >65 years, SHR for death from DTC and death from other 
causes = 14.15 [4.08–49.04] and 6.43 [3.55–1.64], respectively; all p < 0.05). Higher T, N, and M classifications 
were associated with a greater probability of death from DTC, as expected (T4 classification, SHR = 85.64 [9.88–
742.4]; N1b classification, SHR = 9.07 [1.97–41.67]; and M1 classification, SHR = 5.70 [1.55–21.02], with refer-
ence to T1, N0, and M0 classifications, respectively; all p < 0.01), but were not associated with death from other 
causes. A higher number of comorbidities was associated with a high probability of death from other causes 
(number of comorbidities 1–2, SHR = 2.48 [1.46–4.20]; number of comorbidities ≥3, SHR = 9.41 [4.53–19.56]; 
both p < 0.01). Notably, a very high number of comorbidities (≥3) was also associated with extremely low proba-
bility of death from DTC (SHR = 6.81e-10 [1.87e-10–2.48e-9], p < 0.01). These results suggest that patients with 
many comorbidities had very low chances of dying from DTC because they were likely to die earlier from their 
comorbidities. We additionally performed the analysis using the Charlson comorbidity index instead of the num-
ber of comorbidities for generalization (Supplementary Table 2). The analyses showed similar results: patients 
with a score of four to five points on the Charlson comorbidity index had a high probability of death from other 
causes (SHR = 15.06 [4.24–53.53], p < 0.01) and a low probability of death from DTC (SHR = 2.15e-7 [3.85e-8–
1.20e-6], p < 0.01).
Combined influence of TNM stage and the number of comorbidities on death from DTC, death 
from other causes, and overall death. To visualize the combined effects of DTC severity and the number 
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Characteristics Values
Age at thyroidectomy, years1 45.6 ± 13.1
Age group3
   <45 years 998 (48.2%)
   45–55 years 585 (28.3%)
   55–65 years 330 (15.9%)
   65–75 years 134 (6.5%)
   ≥75 years 23 (1.1%)
Follow up duration, years2 12.8 (11.7–14.1)
Gender3
   Female 1751 (84.6%)
   Male 319 (15.4%)
T classification3
   T1 1436 (69.4%)
   T2 278 (13.4%)
   T3a 31 (1.5%)
   T3b 202 (9.8%)
   T4a 123 (5.9%)
   T4b 0 (0.0%)
N classification3
   N0 742 (35.8%)
   N1a 884 (42.7%)
   N1b 444 (21.4%)
M classification3
   M0 2050 (99.0%)
   M1 20 (1.0%)
TNM stage3
   I 1734 (83.8%)
   II 273 (13.2%)
   III 54 (2.6%)
   IV 9 (0.4%)
Histology3
   Papillary thyroid carcinoma 2042 (98.6%)
   Follicular thyroid carcinoma 27 (1.3%)
   Hürthle cell carcinoma 1 (0.0%)
Preoperative comorbidities3
   Malignancies other than DTC 87 (4.2%)
   Hypertension 417 (20.1%)
   Coronary artery occlusive disease 15 (0.7%)
   Peripheral vascular disease 0 (0.0%)
   Cerebrovascular accident 15 (0.7%)
   Congestive heart failure 4 (0.2%)
   Valvular heart disease 10 (0.5%)
   Aortic dissection 1 (0.0%)
   Atrial fibrillation 9 (0.4%)
   Diabetes mellitus (any) 108 (5.2%)
   Diabetes mellitus with chronic complications 18 (0.9%)
   Chronic viral hepatitis 81 (3.9%)
   Liver cirrhosis 2 (0.1%)
   Asthma 22 (1.1%)
   Chronic obstructive pulmonary disease 8 (0.4%)
   End-stage renal disease 16 (0.8%)
   Connective tissue disease 4 (0.2%)
   Dementia 2 (0.1%)
   Hemiplegia, paraplegia, and quadriplegia 2 (0.1%)
   Peptic ulcer disease 0 (0.0%)
   Acquired immunodeficiency syndrome 0 (0.0%)
Total number of comorbidities in each patient3
Continued
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of baseline comorbidities, we stratified patients according to the AJCC/UICC TNM stage and number of baseline 
comorbidities (Fig. 3). The frequency of each comorbidity and each cause of death, stratified by the TNM stage, 
is shown in Supplementary Tables 3 and 4. In this stratified plotting, the cumulative incidence of overall death 
increased when TNM stage or the number of comorbidities increased. In the groups without comorbidities, death 
from DTC accounted for a substantial proportion of the overall death, depending on the TNM stage (Fig. 3A,D,G; 
15-year cumulative incidence of death from DTC/overall death = 0.3%/2.3% for TNM stage I, 5.9%/12.5% for 
TNM stage II, and 14.1%/18.1% for TNM stage III/IV). However, in the groups with 1 or 2 comorbidities, the rel-
ative proportion of death from DTC among the overall death was largely reduced (Fig. 3B,E,H; 15-year cumula-
tive incidence of death from DTC/overall death = 0.3%/7.1% for TNM stage I, 2.9%/19.8% for TNM stage II, and 
29.8%/61.6% for TNM stage III/IV). Moreover, death from DTC was not observed in the groups with comorbidi-
ties ≥3, in contrast to the high overall mortality rate in these groups (Fig. 3C,F,I; 15-year cumulative incidence of 
overall death = 41.7% for TNM stage I, 69.7% for TNM stage II, and 50.0% for TNM stage III/IV).
A higher number of comorbidities was associated with a higher cumulative incidence of death from other 
causes and overall death, regardless of the TNM stage of DTC. In particular, in the groups with TNM stage I DTC, 
Characteristics Values
   0 1463 (70.7%)
   1 453 (21.9%)
   2 121 (5.8%)
   ≥3 33 (1.6%)
Table 1. Baseline characteristics of the patient cohort included in this study (N = 2070). Values are shown as 
1mean ± standard deviation, 2median (interquartile range), or 3n (%). TNM, tumor-node-metastasis; DTC, 
differentiated thyroid carcinoma.
Figure 1. Cumulative incidence curves (CIC) of death from differentiated thyroid carcinoma (DTC) and death 
from other causes. The cumulative incidence functions are stacked, such the distances between the two curves 
represent the probabilities of death from other causes.
Figure 2. Overall survival curves of patients with thyroid cancer according to the number of comorbidities.
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almost all deaths were from other causes; hence, the cumulative incidences of overall death were largely depend-
ent on the number of comorbidities (Fig. 3A–C).
Discussion
In this study, we found that death from DTC accounted for only a fraction of the total deaths in patients who 
underwent surgery for DTC. Along with the severity of DTC, the baseline comorbidities at the time of surgery 
was also important factors in determining overall mortality. A higher number of comorbidities was mainly asso-
ciated with a higher probability of death from other causes, but was also associated with a lower probability of 
death from DTC.
The management of cancer survivors (those living after a diagnosis of cancer) is becoming an increasingly 
important medical issue2. The number of cancer survivors is expected to increase steadily due to population 
growth, aging, and advances in treatment techniques for cancer2,14. Furthermore, the advance of diagnostic 
techniques and the increased implementation of neck ultrasonography, computed tomography, and fine needle 
aspiration are rapidly increasing the thyroid cancer incidence15–18. Because mortality from thyroid cancer was 
generally stable despite an increasing incidence of papillary thyroid cancers, many thyroid cancer survivors would 
ultimately die from causes other than the thyroid cancer itself19. Edwards et al. reported that comorbidities had 
a greater impact on non-cancer death and overall mortality in patients with local and regional disease compared 
to those with distant metastasis and that the role of comorbidities was more significant in less aggressive cancers, 
such as breast and prostate cancer, than in more aggressive cancers such as lung cancer2. Considering that DTC 
is a relatively indolent cancer, the inference that comorbidities would play an important role in DTC survivors is 
natural.
However, only a few studies have addressed the role of comorbidities in thyroid cancer to date. In 2006, 
Kuijpens et al. analyzed data from 417 patients with thyroid cancer including 353 patients with DTC, and 
reported that comorbidities did not independently affect the crude 5-year survival of patients with thyroid can-
cer20. However, because the study by Kuijpens et al. included medullary and anaplastic thyroid cancers and only 
had a small number of deaths, it was unclear whether the same results would be obtained if the study included a 
sufficient number of deaths in patients with DTC only. Recently, Karadaghy et al. reported that a staging system 
incorporating comorbidities could better predict the overall survival of patients with DTC than the AJCC/UICC 
staging system21. However, the causes of death were not considered in that study.
Variables Number of deaths Hazard ratio (95% CI) P value
Age group
   <55 years (n = 1583) 37 1.00 (reference)
   55–65 years (n = 330) 34 3.15 (1.91–5.20) <0.01
   ≥65 years (n = 157) 52 7.96 (4.86–13.02) <0.01
Sex
   Female (n = 1751) 91
   Male (n = 319) 32 1.76 (1.17–2.65) <0.01
T classification
   T1 (n = 1436) 50 1.00 (reference)
   T2 (n = 278) 22 1.76 (1.05–2.96) 0.03
   T3 (n = 233) 19 1.61 (0.94–2.77) 0.08
   T4 (n = 123) 32 3.50 (2.19–5.60) <0.01
N classification
   N0 (n = 742) 48 1.00 (reference)
   N1a (n = 884) 28 0.80 (0.50–1.30) 0.37
   N1b (n = 444) 47 1.69 (1.09–2.60) 0.02
M classification
   M0 (n = 2050) 116 1.00 (reference)
   M1 (n = 20) 7 3.35 (1.49–7.52) <0.01
Histology
   PTC (n = 2042) 117 1.00 (reference)
   FTC or HCC (n = 28) 6 2.20 (0.91–5.32) 0.08
Number of comorbidities
   0 (n = 1463) 42 1.00 (reference)
   1–2 (n = 574) 67 1.95 (1.27–2.99) <0.01
   ≥3 (n = 33) 14 5.33 (2.71–10.46) <0.01
Table 2. Multivariable Cox proportional hazards model for the overall risk of death. Hazard ratios for all-
cause mortality according to tumor-node-metastasis (TNM) classification and the number of comorbidities 
were adjusted for age (<55, 55–65, and ≥65 years), sex, and histological type. CI, confidential interval; PTC, 
papillary thyroid carcinoma; FTC, Follicular thyroid carcinoma; HCC, Hürthle cell carcinoma. Significant 
hazard ratios are indicated in boldface font.
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In our cohort, the 15-year cumulative incidence of overall death was 7.3%, but death from DTC accounted 
for only 1.6% (about one-fifth of overall deaths), despite excluding papillary thyroid microcarcinoma without 
metastases and NIFTP from the cohort. This relative proportion of cancer-specific death to overall death is com-
parable to that of localized breast or prostate cancer and far lower than that of regional cancer, distant cancer, and 
localized colorectal and lung cancer2. This finding suggests that medical problems other than DTC play a great 
role in the overall health of patients with DTC.
In subsequent analyses, we found that baseline comorbidities lower overall survival, independent of the TNM 
classification of DTC. This is in agreement with the report by Karadaghy et al., in which the severity of comor-
bidities had a predictive role for the overall survival of patients with DTC21. A higher number of comorbidities 
was associated with a higher probability of death from causes other than DTC, but did not increase deaths from 
DTC itself. Furthermore, a very high number of comorbidities (≥3) lowered the likelihood of death from DTC. 
In a situation with competing risks, the probability of one outcome is influenced by the risk of the other out-
comes11,12,22. In a recent controversy about the increased mortality rate from thyroid cancer in Japan, Davies et 
al. suggested that this phenomenon may be due to long life expectancies and lower mortality rates from other 
causes23. Inversely, our results demonstrate that patients with multiple comorbidities may have a low likelihood of 
dying from DTC because they are more likely to die earlier from their comorbidities.
The roles of comorbidities and deaths from other causes were more pronounced in patients with a lower stage 
of DTC. It is notable that almost all observed deaths in patients with stage I DTC were from causes other than 
DTC. Death from other causes also accounted for most of the overall deaths in patients with stage II DTC. Thus, 
overall mortality in patients with stage I/II DTC was largely dependent on the number of comorbidities. These 
results suggest that special attention should be paid to the comorbidities of patients with early-stage DTC that 
account for the majority of all DTC cases.
Older age is a well-recognized prognostic determinant of cancer-specific death in DTC24,25, which was also 
observed in our study. However, older age was also associated with a greater probability of a death from other 
causes. Therefore, in older patients, a balanced clinical approach is needed to consider the possibility of death 
from both DTC and other causes.
There were several limitations to this study. Because this was a single-center study, there could be selection 
bias depending on the patients’ visiting patterns or the treatment patterns. Because we only included patients 
who underwent thyroidectomy, our results should not be directly generalized to patients under active surveil-
lance. Because most patients included in our study had papillary thyroid carcinoma, the study results should be 
Variables
Death from DTC Death from other causes
Number 
of deaths Subhazard ratio (95% CI) P value
Number 
of deaths
Subhazard ratio 
(95% CI) P value
Age group
   <55 years (n = 1583) 6 1.00 (reference) 31 1.00 (reference)
   55–65 years (n = 330) 8 4.83 (1.40–16.61) 0.01 26 2.69 (1.51–4.81) <0.01
   ≥65 years (n = 157) 14 14.15 (4.08–49.04) <0.01 38 6.43 (3.55–11.64) <0.01
Sex
   Female (n = 1751) 19 1.00 (reference) 72 1.00 (reference)
   Male (n = 319) 9 1.38 (0.54–3.52) 0.50 23 1.69 (1.06–2.69) 0.03
T classification
   T1 (n = 1436) 1 1.00 (reference) 49 1.00 (reference)
   T2 (n = 278) 3 11.84 (1.22–114.45) 0.03 19 1.70 (1.00–2.90) 0.05
   T3 (n = 233) 4 17.98 (1.96–165.08) 0.01 15 1.28 (0.72–2.27) 0.41
   T4 (n = 123) 20 85.64 (9.88–742.40) <0.01 12 1.28 (0.63–2.57) 0.49
N classification
   N0 (n = 742) 2 1.00 (reference) 46 1.00 (reference)
   N1a (n = 884) 5 4.02 (0.83–19.56) 0.09 23 0.62 (0.37–1.05) 0.07
   N1b (n = 444) 21 9.07 (1.97–41.67) <0.01 26 1.02 (0.60–1.71) 0.95
M classification
   M0 (n = 2050) 24 1.00 (reference) 92 1.00 (reference)
   M1 (n = 20) 4 5.70 (1.55–21.02) <0.01 3 1.60 (0.43–5.93) 0.48
Number of comorbidities
   0 (n = 1463) 13 1.00 (reference) 29 1.00 (reference)
   1–2 (n = 574) 15 0.88 (0.37–2.10) 0.77 52 2.48 (1.46–4.20) <0.01
   ≥ 3 (n = 33) 0 6.81e-10 (1.87e-10–2.48e-9) <0.01 14 9.41 (4.53–19.56) <0.01
Table 3. Multivariable competing risks regression model using the Fine and Gray method for death from DTC 
and death from other causes. Subhazard ratios for death from DTC and death from other causes according to 
tumor-node-metastasis (TNM) classification and the number of comorbidities were adjusted for age (<55, 
55–65, and ≥65 years) and sex. DTC, differentiated thyroid carcinoma; CI, confidential interval. Significant 
subhazard ratios are indicated in boldface font.
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interpreted with caution in patients with other types of DTC. The duration of each comorbidity was not con-
sidered, and each category of comorbidities included many different conditions with different mortality risks. 
However, our results were also supported by additional analysis using Charlson comorbidity index. Changes 
in comorbidities during the follow-up period were not considered; thus, we could not confirm the effects of 
improvement, exacerbation, or emergence of comorbidities or the effects of treatments for comorbidities.
To the best of our knowledge, this is the first study to demonstrate that comorbidities are important factors for 
determining not only the overall survival but also cause of death in patients with DTC, with a large cohort and long 
term follow-up duration. Our study reminds clinicians that comorbidities and mortality risks that are not directly 
related with thyroid cancer could be important medical issues in some thyroid cancer patients. Evaluating and 
considering the comorbidities of a patient with DTC will help the physician to better understand a patient’s overall 
health status and guide clinical decisions regarding follow-up planning for postoperative patients with DTC.
précis. Many patients with differentiated thyroid carcinoma (DTC) ultimately die from comorbidities rather 
than DTC itself. Multiple comorbidities lower the probability of dying from DTC in a competitive manner.
Data Availability
The datasets generated during and/or analyzed during the current study are not publicly available due to protec-
tion of patient information but are available from the corresponding author on reasonable request.
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